☰

Joshua M. Korn, Ph.D.

Affiliations: 
2010 Harvard University, Cambridge, MA, United States 
Area:
structural biology
Google:
"Joshua Korn"
Mean distance: 9.52
 		SNBCP
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor
James M. Hogle grad student 2010 Harvard
 (Copy Number Variation in the Human Genome: Tools, Methods, and Applications to Disease.)

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Palmer AC, Plana D, Gao H, et al. (2020) A proof of concept for biomarker-guided targeted therapy against ovarian cancer based on patient-derived tumor xenografts. Cancer Research
Ye LF, Reznik E, Korn JM, et al. (2020) Patient-derived glioblastoma cultures as a tool for small-molecule drug discovery. Oncotarget. 11: 443-451
Raoof S, Mulford IJ, Frisco-Cabanos H, et al. (2019) Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene
Ghandi M, Huang FW, Jané-Valbuena J, et al. (2019) Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature
Bhang HC, DiMare MT, Kodack DP, et al. (2019) Abstract 394: In vivo shRNA screens under treatment pressure by BRAF and MEK inhibitors to identify novel combination treatment strategies for BRAF-mutant colorectal cancer Cancer Research. 79: 394-394
Cotton JL, KrishnamurthyRadhakrishna V, Chen J, et al. (2019) Abstract A122: Molecular barcoding and single cell approaches to investigate drug tolerance in EGFRmut NSCLC Molecular Cancer Therapeutics. 18
Liu H, Golji J, Brodeur LK, et al. (2018) Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss. Nature Medicine
de Weck A, Golji J, Jones MD, et al. (2018) Correction of copy number induced false positives in CRISPR screens. Plos Computational Biology. 14: e1006279
Shao W, Mishina Y, Feng Y, et al. (2018) Antitumor properties of RAF709, a highly selective and potent inhibitor of RAF kinase dimers, in tumors driven by mutant RAS or BRAF. Cancer Research
Stuart DD, Shao W, Mishina Y, et al. (2018) Abstract DDT01-04: Pharmacological profile and anti-tumor properties of LXH254, a highly selective RAF kinase inhibitor Cancer Research. 78
See more...